Production (Stage)
Dr. Reddy's Laboratories Limited
RDY
$15.80
-$0.37-2.29%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.85B | 3.72B | 3.60B | 3.47B | 3.37B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.85B | 3.72B | 3.60B | 3.47B | 3.37B |
| Cost of Revenue | 1.60B | 1.51B | 1.46B | 1.42B | 1.40B |
| Gross Profit | 2.25B | 2.21B | 2.13B | 2.05B | 1.98B |
| SG&A Expenses | 1.11B | 1.08B | 1.03B | 985.56M | 929.01M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -33.30M | -25.24M | -26.10M | -24.02M | -27.98M |
| Total Operating Expenses | 3.00B | 2.89B | 2.78B | 2.67B | 2.57B |
| Operating Income | 852.07M | 833.27M | 814.89M | 799.04M | 799.01M |
| Income Before Tax | 908.01M | 869.20M | 866.64M | 869.25M | 868.36M |
| Income Tax Expenses | 231.43M | 218.59M | 216.57M | 200.32M | 195.59M |
| Earnings from Continuing Operations | 676.59 | 650.61 | 650.07 | 668.92 | 672.77 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -8.40M | -9.17M | -10.29M | -- | -- |
| Net Income | 668.18M | 641.44M | 639.78M | 668.92M | 672.77M |
| EBIT | 852.07M | 833.27M | 814.89M | 799.04M | 799.01M |
| EBITDA | 1.04B | 1.01B | 984.25M | 966.78M | 964.51M |
| EPS Basic | 0.80 | 0.77 | 0.77 | 0.80 | 0.81 |
| Normalized Basic EPS | 0.66 | 0.64 | 0.63 | 0.63 | 0.63 |
| EPS Diluted | 0.80 | 0.77 | 0.77 | 0.80 | 0.81 |
| Normalized Diluted EPS | 0.66 | 0.64 | 0.63 | 0.63 | 0.63 |
| Average Basic Shares Outstanding | 3.33B | 3.33B | 3.33B | 3.33B | 3.33B |
| Average Diluted Shares Outstanding | 3.34B | 3.34B | 3.34B | 3.34B | 3.33B |
| Dividend Per Share | 0.09 | 0.10 | 0.10 | 0.10 | 0.10 |
| Payout Ratio | 11.90% | 12.40% | 12.43% | 12.02% | 11.95% |